Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00490958Phase 4Completed
Phase 4, randomised, double-blind trial in heart failure (HF) comparing Telmisartan + ACE inhibitor with Placebo + ACE inhibitor (2 arms). Primary endpoints: All-cause mortality at 36 months, Cardiovascular mortality at 36 months and 1 more. Started Jan 1999; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00490958.